Literature DB >> 21447380

Naloxone-precipitated morphine withdrawal behavior and brain IL-1β expression: comparison of different mouse strains.

Liang Liu1, Janet K Coller, Linda R Watkins, Andrew A Somogyi, Mark R Hutchinson.   

Abstract

The development of opioid dependence involves classical neuronal opioid receptor activation and is due in part to engagement of glia causing a proinflammatory response. Such opioid-induced glial activation occurs, at least in part, through a non-classical opioid mechanism involving Toll-like-receptor 4 (TLR4). Among the immune factors released following the opioid-glia-TLR4 interaction, interleukin-1β (IL-1β) plays a prominent role. Previous animal behavioral studies have demonstrated significant heterogeneity of chronic morphine-induced tolerance and dependence between different mouse strains. The aim of this study was to investigate whether the heterogeneity of chronic opioid-induced IL-1β expression contributes to differences in opioid tolerance and withdrawal behaviors. Chronic morphine-induced tolerance and dependence were assessed in 3 inbred wild-type mouse strains (Balb/c, CBA, and C57BL/6) and 2 knockout strains (TLR4 and MyD88). Analysis of brain nuclei (medial prefrontal cortex, cortex, brain stem, hippocampus, and midbrain and diencephalon regions combined) revealed that, of inbred wild-type mice, there are significant main effects of morphine treatment on IL-1β expression in the brain regions analyzed (p<0.02 for all regions analyzed). A significant increase in hippocampal IL-1β expression was found in C57BL/6 mice after morphine treatment, whilst, a significant decrease was found in the mPFC region of wild-type Balb/c mice. Furthermore, the results of wild-type inbred strains demonstrated that the elevated hippocampal IL-1β expression is associated with withdrawal jumping behavior. Interestingly, knockout of TLR4, but not MyD88 protected against the development of analgesic tolerance. Gene sequence differences of IL - 1β and TLR4 genes alone did not explain the heterogeneity of dependence behavior between mouse strains. Together, these data further support the involvement of opioid-induced CNS immune signaling in dependence development. Moreover, this study demonstrated the advantages of utilizing multiple mouse strains and indicates that appropriate choice of mouse strains could enhance future research outcomes.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21447380      PMCID: PMC3142610          DOI: 10.1016/j.bbi.2011.03.016

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  34 in total

Review 1.  The "toll" of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia.

Authors:  Linda R Watkins; Mark R Hutchinson; Kenner C Rice; Steven F Maier
Journal:  Trends Pharmacol Sci       Date:  2009-09-15       Impact factor: 14.819

Review 2.  Interleukin-1 (IL-1) pathway.

Authors:  Axel Weber; Peter Wasiliew; Michael Kracht
Journal:  Sci Signal       Date:  2010-01-19       Impact factor: 8.192

3.  Minocycline suppresses morphine-induced respiratory depression, suppresses morphine-induced reward, and enhances systemic morphine-induced analgesia.

Authors:  Mark R Hutchinson; Alexis L Northcutt; Lindsey W Chao; Jeffrey J Kearney; Yingning Zhang; Debra L Berkelhammer; Lisa C Loram; Robert R Rozeske; Sondra T Bland; Steven F Maier; Todd T Gleeson; Linda R Watkins
Journal:  Brain Behav Immun       Date:  2008-07-31       Impact factor: 7.217

4.  Proinflammatory cytokines oppose opioid-induced acute and chronic analgesia.

Authors:  Mark R Hutchinson; Benjamen D Coats; Susannah S Lewis; Yingning Zhang; David B Sprunger; Niloofar Rezvani; Eric M Baker; Brian M Jekich; Julie L Wieseler; Andrew A Somogyi; David Martin; Stephen Poole; Charles M Judd; Steven F Maier; Linda R Watkins
Journal:  Brain Behav Immun       Date:  2008-07-02       Impact factor: 7.217

5.  Reduction of opioid withdrawal and potentiation of acute opioid analgesia by systemic AV411 (ibudilast).

Authors:  Mark R Hutchinson; Susannah S Lewis; Benjamen D Coats; David A Skyba; Nicole Y Crysdale; Debra L Berkelhammer; Anita Brzeski; Alexis Northcutt; Christine M Vietz; Charles M Judd; Steven F Maier; Linda R Watkins; Kirk W Johnson
Journal:  Brain Behav Immun       Date:  2008-10-04       Impact factor: 7.217

6.  The glial activation inhibitor AV411 reduces morphine-induced nucleus accumbens dopamine release.

Authors:  Sondra T Bland; Mark R Hutchinson; Steven F Maier; Linda R Watkins; Kirk W Johnson
Journal:  Brain Behav Immun       Date:  2009-02-03       Impact factor: 7.217

7.  Evidence that opioids may have toll-like receptor 4 and MD-2 effects.

Authors:  Mark R Hutchinson; Yingning Zhang; Mitesh Shridhar; John H Evans; Madison M Buchanan; Tina X Zhao; Peter F Slivka; Benjamen D Coats; Niloofar Rezvani; Julie Wieseler; Travis S Hughes; Kyle E Landgraf; Stefanie Chan; Stephanie Fong; Simon Phipps; Joseph J Falke; Leslie A Leinwand; Steven F Maier; Hang Yin; Kenner C Rice; Linda R Watkins
Journal:  Brain Behav Immun       Date:  2009-08-11       Impact factor: 7.217

8.  Genetic correlates of morphine withdrawal in 14 inbred mouse strains.

Authors:  Pamela Metten; John C Crabbe; John K Belknap
Journal:  Drug Alcohol Depend       Date:  2008-09-06       Impact factor: 4.492

9.  Toll-like receptor 2 is required for opioids-induced neuronal apoptosis.

Authors:  Yi Li; Hui Li; Yi Zhang; Xiuli Sun; Gregory A Hanley; Gene LeSage; Ying Zhang; Shenggang Sun; Ying Peng; Deling Yin
Journal:  Biochem Biophys Res Commun       Date:  2009-11-13       Impact factor: 3.575

10.  Association of IL-1B genetic polymorphisms with an increased risk of opioid and alcohol dependence.

Authors:  Liang Liu; Mark R Hutchinson; Jason M White; Andrew A Somogyi; Janet K Coller
Journal:  Pharmacogenet Genomics       Date:  2009-11       Impact factor: 2.089

View more
  28 in total

1.  Role of phosphodiesterase inhibitor Ibudilast in morphine-induced hippocampal injury.

Authors:  Mohsen Zhaleh; Marzieh Panahi; Mehri Ghafurian Broujerdnia; Rostam Ghorbani; Kambiz Ahmadi Angali; Ghasem Saki
Journal:  J Inj Violence Res       Date:  2013-10-11

2.  The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid-dependent volunteers.

Authors:  Ziva D Cooper; Kirk W Johnson; Martina Pavlicova; Andrew Glass; Suzanne K Vosburg; Maria A Sullivan; Jeanne M Manubay; Diana M Martinez; Jermaine D Jones; Phillip A Saccone; Sandra D Comer
Journal:  Addict Biol       Date:  2015-05-14       Impact factor: 4.280

3.  Modulation of histone deacetylase attenuates naloxone-precipitated opioid withdrawal syndrome.

Authors:  Ashish K Rehni; Nirmal Singh; Mahesh Rachamalla; Kulbhushan Tikoo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-02-25       Impact factor: 3.000

4.  Morphine activates neuroinflammation in a manner parallel to endotoxin.

Authors:  Xiaohui Wang; Lisa C Loram; Khara Ramos; Armando J de Jesus; Jacob Thomas; Kui Cheng; Anireddy Reddy; Andrew A Somogyi; Mark R Hutchinson; Linda R Watkins; Hang Yin
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-02       Impact factor: 11.205

5.  Inflammasome Activation by Methamphetamine Potentiates Lipopolysaccharide Stimulation of IL-1β Production in Microglia.

Authors:  Enquan Xu; Jianuo Liu; Han Liu; Xiaobei Wang; Huangui Xiong
Journal:  J Neuroimmune Pharmacol       Date:  2018-02-28       Impact factor: 4.147

6.  Opioid activation of toll-like receptor 4 contributes to drug reinforcement.

Authors:  M R Hutchinson; A L Northcutt; T Hiranita; X Wang; S S Lewis; J Thomas; K van Steeg; T A Kopajtic; L C Loram; C Sfregola; E Galer; N E Miles; S T Bland; J Amat; R R Rozeske; T Maslanik; T R Chapman; K A Strand; M Fleshner; R K Bachtell; A A Somogyi; H Yin; J L Katz; K C Rice; S F Maier; L R Watkins
Journal:  J Neurosci       Date:  2012-08-15       Impact factor: 6.167

Review 7.  Neuroimmune mechanisms of psychostimulant and opioid use disorders.

Authors:  Rebecca S Hofford; Scott J Russo; Drew D Kiraly
Journal:  Eur J Neurosci       Date:  2018-09-26       Impact factor: 3.386

8.  Dorsal hippocampal interleukin-1 signaling mediates heroin withdrawal-enhanced fear learning.

Authors:  Shveta V Parekh; Jacqueline E Paniccia; Christina L Lebonville; Donald T Lysle
Journal:  Psychopharmacology (Berl)       Date:  2020-08-28       Impact factor: 4.530

9.  CCL5 and cytokine expression in the rat brain: differential modulation by chronic morphine and morphine withdrawal.

Authors:  Lee A Campbell; Valeriya Avdoshina; Summer Rozzi; Italo Mocchetti
Journal:  Brain Behav Immun       Date:  2013-08-19       Impact factor: 7.217

10.  In vivo and in vitro attenuation of naloxone-precipitated experimental opioid withdrawal syndrome by insulin and selective KATP channel modulator.

Authors:  Prabhat Singh; Bhupesh Sharma; Surbhi Gupta; B M Sharma
Journal:  Psychopharmacology (Berl)       Date:  2014-07-26       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.